ID

37414

Descripción

Effect of Dapagliflozin on 24-hour Blood Glucose in T2DM Patients Inadequately Controlled With Either Metformin Or Insulin; ODM derived from: https://clinicaltrials.gov/show/NCT02429258

Link

https://clinicaltrials.gov/show/NCT02429258

Palabras clave

Versiones (1)
  1. 24/7/19 24/7/19 -
Titular de derechos de autor

See clinicaltrials.gov

Subido en

24 de julio de 2019

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Type II Diabetes NCT02429258

Inglés

Eligibility Type II Diabetes NCT02429258

1 formularios  
Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
type 2 diabetes mellitus (t2dm)
Descripción

Diabetes Mellitus, Non-Insulin-Dependent

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0011860
treated with either stable dose of metformin alone > or = to 1500mg/day or stable dose of insulin > or = to 30 units/day and up to 2oad medications for at least 8 weeks
Descripción

Metformin Dose Stable U/day | Insulin Dose Stable U/day | Antidiabetics Oral Quantity

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0025598
UMLS CUI [1,2]
C0178602
UMLS CUI [1,3]
C0205360
UMLS CUI [1,4]
C0456683
UMLS CUI [2,1]
C0021641
UMLS CUI [2,2]
C0178602
UMLS CUI [2,3]
C0205360
UMLS CUI [2,4]
C0456683
UMLS CUI [3,1]
C0935929
UMLS CUI [3,2]
C1527415
UMLS CUI [3,3]
C1265611
hemoglobin a1c (hba1c) 7.5% to 10.5% at screening
Descripción

Hemoglobin A1c measurement

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0474680
body mass index (bmi) < or = to 45 kg/m2
Descripción

Body mass index

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1305855
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
for patients who enter the study taking a stable dose of metformin, history of taking oad medications other than metformin during the 8 weeks prior to screening or have been on insulin therapy within 1 year of screening
Descripción

Metformin Dose Stable | Antidiabetics Oral | Exception Metformin | Insulin regime

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0025598
UMLS CUI [1,2]
C0178602
UMLS CUI [1,3]
C0205360
UMLS CUI [2,1]
C0935929
UMLS CUI [2,2]
C1527415
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0025598
UMLS CUI [4]
C0557978
for patients who enter the study taking insulin, history of taking any other therapy outside of the stable insulin and up to 2 oad medications for 8 weeks prior to screening.
Descripción

Insulin | Therapy Except Insulin | Therapy Except Antidiabetics Oral

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0021641
UMLS CUI [2,1]
C0087111
UMLS CUI [2,2]
C0332300
UMLS CUI [2,3]
C0021641
UMLS CUI [3,1]
C0087111
UMLS CUI [3,2]
C0332300
UMLS CUI [3,3]
C0935929
UMLS CUI [3,4]
C1527415
use of sulfonylureas during the 8 weeks prior to screening
Descripción

Sulfonylureas

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0038766
prior exposure to dapagliflozin or any sodium-glucose co-transporter 2 (sglt-2) inhibitor
Descripción

Exposure to Dapagliflozin | Exposure to SGLT2 Inhibitor

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0332157
UMLS CUI [1,2]
C2353951
UMLS CUI [2,1]
C0332157
UMLS CUI [2,2]
C3273807
ingestion of any medication know to affect glucose metabolism for >7 consecutive days during the 3 months prior to screening
Descripción

Pharmaceutical Preparations Affecting Glucose metabolism

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0013227
UMLS CUI [1,2]
C0392760
UMLS CUI [1,3]
C0596620
ingestion of prescription or over the counter weight loss medication during 3 months prior to screening
Descripción

Weight-Loss Agents prescribed | Weight-Loss Agents Non-Prescription

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0376606
UMLS CUI [1,2]
C0278329
UMLS CUI [2,1]
C0376606
UMLS CUI [2,2]
C0013231
Volver a la parte superior de la página

Similar models

Eligibility Type II Diabetes NCT02429258

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
Diabetes Mellitus, Non-Insulin-Dependent
Item
type 2 diabetes mellitus (t2dm)
boolean
C0011860 (UMLS CUI [1])
Metformin Dose Stable U/day | Insulin Dose Stable U/day | Antidiabetics Oral Quantity
Item
treated with either stable dose of metformin alone > or = to 1500mg/day or stable dose of insulin > or = to 30 units/day and up to 2oad medications for at least 8 weeks
boolean
C0025598 (UMLS CUI [1,1])
C0178602 (UMLS CUI [1,2])
C0205360 (UMLS CUI [1,3])
C0456683 (UMLS CUI [1,4])
C0021641 (UMLS CUI [2,1])
C0178602 (UMLS CUI [2,2])
C0205360 (UMLS CUI [2,3])
C0456683 (UMLS CUI [2,4])
C0935929 (UMLS CUI [3,1])
C1527415 (UMLS CUI [3,2])
C1265611 (UMLS CUI [3,3])
Hemoglobin A1c measurement
Item
hemoglobin a1c (hba1c) 7.5% to 10.5% at screening
boolean
C0474680 (UMLS CUI [1])
Body mass index
Item
body mass index (bmi) < or = to 45 kg/m2
boolean
C1305855 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Metformin Dose Stable | Antidiabetics Oral | Exception Metformin | Insulin regime
Item
for patients who enter the study taking a stable dose of metformin, history of taking oad medications other than metformin during the 8 weeks prior to screening or have been on insulin therapy within 1 year of screening
boolean
C0025598 (UMLS CUI [1,1])
C0178602 (UMLS CUI [1,2])
C0205360 (UMLS CUI [1,3])
C0935929 (UMLS CUI [2,1])
C1527415 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0025598 (UMLS CUI [3,2])
C0557978 (UMLS CUI [4])
Insulin | Therapy Except Insulin | Therapy Except Antidiabetics Oral
Item
for patients who enter the study taking insulin, history of taking any other therapy outside of the stable insulin and up to 2 oad medications for 8 weeks prior to screening.
boolean
C0021641 (UMLS CUI [1])
C0087111 (UMLS CUI [2,1])
C0332300 (UMLS CUI [2,2])
C0021641 (UMLS CUI [2,3])
C0087111 (UMLS CUI [3,1])
C0332300 (UMLS CUI [3,2])
C0935929 (UMLS CUI [3,3])
C1527415 (UMLS CUI [3,4])
Sulfonylureas
Item
use of sulfonylureas during the 8 weeks prior to screening
boolean
C0038766 (UMLS CUI [1])
Exposure to Dapagliflozin | Exposure to SGLT2 Inhibitor
Item
prior exposure to dapagliflozin or any sodium-glucose co-transporter 2 (sglt-2) inhibitor
boolean
C0332157 (UMLS CUI [1,1])
C2353951 (UMLS CUI [1,2])
C0332157 (UMLS CUI [2,1])
C3273807 (UMLS CUI [2,2])
Pharmaceutical Preparations Affecting Glucose metabolism
Item
ingestion of any medication know to affect glucose metabolism for >7 consecutive days during the 3 months prior to screening
boolean
C0013227 (UMLS CUI [1,1])
C0392760 (UMLS CUI [1,2])
C0596620 (UMLS CUI [1,3])
Weight-Loss Agents prescribed | Weight-Loss Agents Non-Prescription
Item
ingestion of prescription or over the counter weight loss medication during 3 months prior to screening
boolean
C0376606 (UMLS CUI [1,1])
C0278329 (UMLS CUI [1,2])
C0376606 (UMLS CUI [2,1])
C0013231 (UMLS CUI [2,2])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial